Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

556

Enrollment

INDUSTRY

Sponsor class

Stopped Numerically modest lowering of HbA1c with canakinumab in combination with metformin was inadequate to continue patients with T2DM into Period IV of this study.

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Canakinumab
DRUG: Metformin
DRUG: Placebo

Sponsor

Novartis